Insulet Announces Board and Management Changes

Insulet Corporation, developer of tubeless insulin pump technology with its Omnipod Insulin Management System, has announced changes to the responsibilities of key members of its Board of Directors and management team:
 

• Patrick Sullivan, president and CEO since September 2014, has been elected board chairman. He will continue to serve as CEO.
• Dr. Jessica Hopfield, a board director since July 2015, has been appointed lead independent director of the board. Hopfield succeeds Dr. John Fallon, who will continue to serve on the board as an independent director. Hopfield also chairs the Board of Trustees of the Joslin Diabetes Center and is a strategic advisor and investor in startup healthcare firms. She previously was a partner of McKinsey & Company in its Global Pharmaceuticals and Medical Devices Practice.
• Shacey Petrovic, president of Diabetes Products since February 2016 after joining the company as chief commercial officer in February 2015, has been promoted to president and chief operating officer. In this position, she will work closely with Sullivan to further improve Insulet’s operational capabilities and capitalize on new growth opportunities, and will be responsible for overseeing the company’s Drug Delivery product line.
• Daniel Levangie, president of Drug Delivery, has informed the company he will retire at the end of 2016. Petrovic will assume Levangie’s responsibilities and Levangie will continue with the company through the end of the year to assist with an effective transition. He will then remain available to the company in a consulting role.
   

“I am pleased the board has appointed Dr. Jessica Hopfield as lead independent director and I thank Dr. John Fallon for his service. As the newly elected chairman, I look forward to working closely with Jessica, John and our fellow board members to continue advancing Insulet’s growth and success,” Sullivan said. “I am also excited to promote Shacey to her new position of president and chief operating officer. Since joining Insulet, she has demonstrated tremendous leadership, overseeing the realignment of our commercial operations, a reset of our product development roadmap and record-breaking commercial results. The further expansion of Shacey’s management responsibilities recognizes her valuable skillset and the meaningful contributions she is making to Insulet’s growth. We believe the company will benefit from a unified approach to developing insulin and non-insulin commercial opportunities for our technology platform and Shacey is the ideal person to oversee this initiative.”
 
“Dan has been an invaluable member of the Insulet team, leading the drug delivery business through a time of transition and overseeing the development of a long-term strategy for the franchise. His contributions have significantly advanced our drug delivery business and through his roles on the senior leadership team and previously as a member of our Board of Directors, Dan has helped shape our overall company strategy and organization,” Sullivan added. “On behalf of the entire board and management team, I thank Dan for his commitment to Insulet and wish him all the best.”
 
Insulet Corporation’s Omnipod Insulin Management System, is designed to help to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet’s Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Mass.